|
See related Advate powd for inj information |
|
|
|
Manufacturer |
Baxter Healthcare |
|
Distributor |
Hong Kong: Baxter Healthcare/Macau: Firma Chun Cheong |
|
Contents |
Octocog alfa (recombinant human coagulation factor VIII) |
|
Indications |
Prevention or treatment of spontaneous or surgery-related bleeding in patients w/ haemophilia A. |
|
Dosage |
IV Individualised dosage. Prevention of bleeding 20-40 IU/kg body wt every 2-3 days. Early haemarthrosis, muscle or oral bleeding 20-40% or IU/dL every 12-24 hr (8-24 hr for patient <6 yr) for at least 1 day. More extensive haemarthrosis, muscle bleeding or haematoma 30-60% or IU/dL every 12-24 hr (8-24 hr for patient <6 yr) for ≥3-4 days. Life-threatening haemorrhage 60-100% or IU/dL every 8-24 hr (6-12 hr for patient <6 yr). Minor surgery 30-60% or IU/dL every 24 hr (12-24 hr for patient <6 yr) for at least 1 day. Major surgery 80-100% or IU/dL (pre-op & post-op) every 8-24 hr (6-24 hr for patient <6 yr) until adequate wound healing, then continue therapy for another 7 days. |
|
Contraindications |
Hypersensitivity to mouse or hamster proteins. |
|
Special Precautions |
Monitor patients for development of factor VIII inhibitors. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Dizziness, headache, fever.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
B02BD02 - coagulation factor VIII ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Advate powder for injection |
|
|
|
Manufacturer: |
Baxter Healthcare |
|
Distributor: |
Hong Kong: Baxter Healthcare
Macau: Firma Chun Cheong
|
|
|
|
